《国际指南：静脉注射免疫球蛋白在治疗Rh和ABO新生儿溶血病中的作用》解读

doi:10.7499/j.issn.1008-8830.2205158

摘要
图/表
参考文献(35)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (511 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要《国际指南：静脉注射免疫球蛋白在治疗Rh和ABO新生儿溶血病中的作用》由血液学家、新生儿科医生和输血科专家共同组成的国际专家小组起草，2022年3月16日发表于《英国血液学杂志》。该指南针对静脉注射免疫球蛋白（intravenous immunoglobulin，IVIG）用于Rh和ABO新生儿溶血病进行了循证证据总结并提出了推荐意见。该指南推荐IVIG不应常规应用于Rh和ABO新生儿溶血病以减少换血（exchange transfusion，ET）；在合并严重高胆红素血症（接近或超过ET阈值）或无法实施ET的情况下，IVIG的最佳使用时机尚不明确。该指南制定方法规范严谨，但现有的证据质量等级不高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄方俊
	何洋
	唐军
	张萌
	陈剑
	母得志

关键词 ：静脉注射免疫球蛋白, 新生儿溶血病, 国际指南, 新生儿

Abstract：International guidelines regarding the role of intravenous immunoglobulin (IVIG) in the management of Rh- and ABO-mediated haemolytic disease of the newborn was drafted by an international panel of experts in the fields of hematology, neonatology, and blood transfusion and was published in British Journal of Haematology on March 16, 2022. The guidelines summarize the evidence-based practice of IVIG in Rh- and ABO-mediated haemolytic disease of the newborn and propose related recommendations. The guidelines recommend that IVIG should not be applied as a routine treatment regimen for Rh- and ABO-mediated haemolytic disease of the newborn in order to reduce exchange transfusion (ET), and the best time to apply IVIG remains unclear in the situations where hyperbilirubinaemia is severe (approaching or exceeding the ET threshold) or ET cannot be implemented. These guidelines are formulated with rigorous methods, but with the lower quality of evidence.

Key words： Intravenous immunoglobulin Haemolytic disease of the newborn International guideline Neonate

收稿日期: 2022-05-27

通讯作者: 唐军，女，主任医师，教授。Email：tj1234753@sina.com。 E-mail: tj1234753@sina.com

作者简介: 黄方俊，女，硕士研究生；

引用本文:

黄方俊,何洋,唐军等. 《国际指南：静脉注射免疫球蛋白在治疗Rh和ABO新生儿溶血病中的作用》解读[J]. 中国当代儿科杂志, 2022, 24(11): 1183-1188.

HUANG Fang-Jun,HE Yang,TANG Jun et al. Interpretation of "International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn"[J]. CJCP, 2022, 24(11): 1183-1188.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2205158 或 http://www.zgddek.com/CN/Y2022/V24/I11/1183

	Webb J, Delaney M. Red blood cell alloimmunization in the pregnant patient[J]. Transfus Med Rev, 2018, 32(4): 213-219. PMID: 30097223. DOI: 10.1016/j.tmrv.2018.07.002.
	Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn[J]. Hematology Am Soc Hematol Educ Program, 2015, 2015: 146-151. PMID: 26637714. DOI: 10.1182/asheducation-2015.1.146.
	3 Kliegman RM, Nelson WE. Nelson Textbook of Pediatrics[M]. 19th ed. Philadelphia, PA, USA: Elsevier/Saunders, 2011: 615-619.
	Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era[J]. Semin Fetal Neonatal Med, 2016, 21(1): 28-34. PMID: 26589360. DOI: 10.1016/j.siny.2015.10.006.
	5 邵肖梅, 叶鸿瑁, 丘小汕, 等. 实用新生儿学[M]. 5版. 北京: 人民卫生出版社, 2019.
	Lieberman L, Callum J, Cohen R, et al. Impact of red blood cell alloimmunization on fetal and neonatal outcomes: a single center cohort study[J]. Transfusion, 2020, 60(11): 2537-2546. PMID: 32893897. DOI: 10.1111/trf.16061.
	Pillai A, Pandita A, Osiovich H, et al. Pathogenesis and management of indirect hyperbilirubinemia in preterm neonates less than 35 weeks: moving toward a standardized approach[J]. Neoreviews, 2020, 21(5): e298-e307. PMID: 32358143. DOI: 10.1542/neo.21-5-e298.
	Zhang M, Tang J, He Y, et al. Systematic review of global clinical practice guidelines for neonatal hyperbilirubinemia[J]. BMJ Open, 2021, 11(1): e040182. PMID: 33468526. PMCID: PMC7817798. DOI: 10.1136/bmjopen-2020-040182.
	Lieberman L, Lopriore E, Baker JM, et al. International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn[J]. Br J Haematol, 2022, 198(1): 183-195. PMID: 35415922. DOI: 10.1111/bjh.18170.
	10 周奇, 邢丹, 李沁原, 等. 指南解读类文献报告规范的制订指南 (RIGHT for INT)[J]. 中国循证医学杂志, 2022, 22(5): 497-507. DOI: 10.7507/1672-2531.202201137.
	Zwiers C, Scheffer-Rath ME, Lopriore E, et al. Immunoglobulin for alloimmune hemolytic disease in neonates[J]. Cochrane Database Syst Rev, 2018, 3(3): CD003313. PMID: 29551014. PMCID: PMC6494160. DOI: 10.1002/14651858.CD003313.pub2.
	Louis D, More K, Oberoi S, et al. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2014, 99(4): F325-F331. PMID: 24514437. DOI: 10.1136/archdischild-2013-304878.
	Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn: a prospective randomized controlled trial[J]. Eur J Pediatr, 2011, 170(4): 461-467. PMID: 20924607. DOI: 10.1007/s00431-010-1310-8.
	Tanyer G, Siklar Z, Dallar Y, et al. Multiple dose IVIG treatment in neonatal immune hemolytic jaundice[J]. J Trop Pediatr, 2001, 47(1): 50-53. PMID: 11245352. DOI: 10.1093/tropej/47.1.50.
	Beken S, Hirfanoglu I, Turkyilmaz C, et al. Intravenous immunoglobulin G treatment in ABO hemolytic disease of the newborn, is it myth or real?[J]. Indian J Hematol Blood Transfus, 2014, 30(1): 12-15. PMID: 24554813. PMCID: PMC3921323. DOI: 10.1007/s12288-012-0186-3.
	Demirel G, Akar M, Celik IH, et al. Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates[J]. Int J Hematol, 2011, 93(6): 700-703. PMID: 21617887. DOI: 10.1007/s12185-011-0853-4.
	American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2004, 114(1): 297-316. PMID: 15231951. DOI: 10.1542/peds.114.1.297.
	18 The GRADE Working Group. Grading of recommendations, assessment, development, and evaluations (GRADE)[EB/OL].[2022-05-06]. https://www.gradeworkinggroup.org/#pub.
	Norris SL; RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. PMID: 27893062. DOI: 10.7326/M16-1565.
	20 National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days[EB/OL]. [2022-05-06]. https://www.nice.org.uk/guidance/CG98/evidence.
	21 Barrington KJ, Sankaran K, Canadian Paediatric Society, et al. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants[J]. Paediatr Child Health, 2007, 12(suppl_B): 1B-12B. DOI: 10.1093/pch/12.suppl_B.1B.
	Romagnoli C, Barone G, Pratesi S, et al. Italian guidelines for management and treatment of hyperbilirubinaemia of newborn infants ≥ 35 weeks' gestational age[J]. Ital J Pediatr, 2014, 40(1): 11. PMID: 24485088. PMCID: PMC4015911. DOI: 10.1186/1824-7288-40-11.
	23 中华医学会儿科学分会新生儿学组, 《中华儿科杂志》编辑委员会. 新生儿高胆红素血症诊断和治疗专家共识[J]. 中华儿科杂志, 2014, 52(10): 745-748. DOI: 10.3760/cma.j.issn.0578-1310.2014.10.006.
	oban A, Türkmen MK, Gürsoy T. Turkish Neonatal Society guideline to the approach, follow-up, and treatment of neonatal jaundice[J]. Turk Pediatri Ars, 2018, 53(Suppl 1): S172-S179. PMID: 31236030. PMCID: PMC6568284. DOI: 10.5152/TurkPediatriArs.2018.01816.
	Sánchez-Redondo Sánchez-Gabriel MD, Leante Castellanos JL, Benavente Fernández I, et al. Guidelines for prevention, detection and management of hyperbilirubinaemia in newborns of 35 or more weeks of gestation[J]. An Pediatr (Barc), 2017, 87(5): 294.e1-294.e8. PMID: 28526241. DOI: 10.1016/j.anpedi.2017.03.006.
	Kaplan M, Merlob P, Regev R. Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus[J]. J Perinatol, 2008, 28(6): 389-397. PMID: 18322551. DOI: 10.1038/jp.2008.20.
	27 Queensland Government . Neonatal jaundice[EB/OL].[2022-05-06]. https://www.health.qld.gov.au/__data/assets/pdf_file/0018/142038/g-jaundice.pdf.
	28 Section M. Management of neonatal jaundice[EB/OL]. [2022-05-06].
	Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn[J]. Acta Paediatr, 2011, 100(4): 499-505. PMID: 21114525. DOI: 10.1111/j.1651-2227.2010.02104.x.
	30 Swiss Society of Neonatology. Assessment and treatment of jaundiced newborn infants 35 0/7 or more weeks of gestation[EB/OL]. [2022-05-06]. https://www.neonet.ch/application/files/6915/6879/9379/2006_Bili-Empfehlungen_e_final.pdf.
	Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions[J]. Arch Dis Child, 2006, 91(8): 651-654. PMID: 16638785. PMCID: PMC2083046. DOI: 10.1136/adc.2005.078733.
	32 Henrickson SE, Law CK. Adverse effects of different formulations of intravenous immunoglobulin[J]. J Allergy Clin Immunol, 2015, 135(Suppl 2): AB92. DOI: 10.1016/j.jaci.2014.12.1232.
	Kumar A, Kapoor R, Basu S. Apnea as a complication of intravenous immunoglobulin therapy in a neonate[J]. Indian J Pediatr, 2014, 81(12): 1415. PMID: 24944148. DOI: 10.1007/s12098-014-1509-1.
	Christensen RD, Ilstrup SJ, Baer VL, et al. Increased hemolysis after administering intravenous immunoglobulin to a neonate with erythroblastosis fetalis due to Rh hemolytic disease[J]. Transfusion, 2015, 55(6): 1365-1366. PMID: 26074177. DOI: 10.1111/trf.13104.
	Figueras-Aloy J, Rodríguez-Miguélez JM, Iriondo-Sanz M, et al. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease[J]. Pediatrics, 2010, 125(1): 139-144. PMID: 19948572. DOI: 10.1542/peds.2009-0676.